Every year, I watch finance directors and HR leaders sit across from their health maintenance organisation (HMO) account managers, dissecting spreadsheets full of premium hikes, claim counts, and costly diagnoses. Yet, almost nobody asks the most fundamental question: are employees actually taking the medicines they were prescribed? Overlooking this detail leaves renewal negotiations trapped in an expensive post-mortem on treatment costs, while completely ignoring the practical access hurdles and day-to-day behaviours that drive future claims.
The blind spot in renewal analysis
Standard renewal packs are predictably backward-looking. They flood you with total claims, inpatient stays, outpatient visits, chronic condition prevalence, provider league tables, and projections for medical trend. These figures matter commercially, but they only record what has already gone wrong. They tell us nothing about whether an employee's condition was clinically managed, whether their therapy was abruptly broken off, or whether they simply abandoned their prescription at the chemist.
The real-world cost of that blind spot across British business is massive. Official labour market statistics from the Office for National Statistics reveal that sickness and injury cost the UK economy 148.9 million working days in 2024, working out at 4.4 lost days per employee. Employees managing long-term health conditions recorded an absence rate of 4.0%, quadruple the 1.0% seen among their healthier colleagues.
Medication continuity sits right at the heart of this link between chronic conditions, clinical intervention, and workplace attendance. Yet boardrooms consistently treat prescription follow-through as an individual clinical issue rather than a structural risk-management issue. The outcome at renewal is a skewed conversation: insurers point to repeated consultations and spiralling costs, while employers assume these soaring health risks are simply inevitable. The question leadership should be asking is what proportion of avoidable deterioration stems directly from poor access, interrupted treatment, or simple confusion over therapies.
Compliance is not the same as adherence
Language matters here, particularly when reviewing benefits data. The term "compliance" carries an unhelpful whiff of paternalism, implying that patients must passively obey doctors' orders. NICE deliberately favours the more collaborative concept of "adherence", which measures how closely a person's routine aligns with agreed medical recommendations. Crucially, NICE guidance recognises that non-adherence is widespread and can be deliberate or entirely accidental.
That difference changes how we manage commercial risk. An uncollected prescription or a missed dose might stem from routine disruption, forgetfulness, unmanaged side effects, ambiguous instructions, fears of dependency, repeat-prescription delays, or prescription charges. Writing off every missed dose as individual negligence guarantees poorly designed workplace health programmes and flawed underwriting assumptions.
NICE explicitly advises clinicians to evaluate adherence without judgement whenever medicines are prescribed, dispensed, or reviewed. Healthcare practitioners are instructed to uncover the precise practical and psychological barriers facing each individual, warning against one-size-fits-all fixes. For an HMO, capturing a medication signal must never mean penalising a worker or blacklisting a team. Its true purpose is pinpointing where targeted clinical reviews, smoother pharmacy channels, better health literacy, or easier workplace access will prevent severe claims later.
Why HMOs rarely provide the data
There are genuine operational reasons why prescription adherence figures rarely make it into annual renewal packs.
To begin with, prescription information carries strict data privacy restrictions. Dispensing records map out a worker's health vulnerabilities and clinical background in precise detail. The NHS Business Services Authority maintains patient-level dispensing registries under tight governance, ensuring public disclosures remain strictly anonymised or aggregated.
Measuring true adherence is technically complex. A picked-up prescription is no guarantee that pills were swallowed, just as a gap between repeats could mean hospital care, an agreed pause, a dosage alteration, or a drawer full of unused medication.
HMO infrastructure is engineered to process transactional claims rather than map continuous care journeys. Most platforms capture fees for a specialist visit, a scan, or an approved drug benefit, yet they have no way of knowing whether a member understood their treatment regime or hit practical roadblocks.
Finally, commercial interests do not align naturally around adherence. Renewal meetings fixate on pricing power, loss ratios, and catastrophic claims. Dedicated medication support often looks like an unwanted administrative overhead to an insurer, even when it cuts out far costlier emergency episodes down the road.
Employers must never demand raw, identifiable prescription trackers. What you need instead is macro-level population intelligence: cohort patterns, risk indicators, refill continuity, and clear intervention metrics, wrapped in airtight data governance.
What the missing signal may reveal
When handled properly, aggregate medication data transforms claims analysis across three distinct operational areas.
First, chronic condition management. Frequent claims for hypertension, asthma, diabetes, or cardiovascular trouble might represent genuine disease progression, or they might expose broken treatment routines and skipped reviews. Viewing anonymised refill cadences and ongoing clinical follow-ups allows leadership to separate genuinely stable cohorts from unmanaged deterioration.
Second, avoidable emergency escalation. A panicked emergency admission or intensive outpatient intervention is merely an end result, not an underlying cause. If cohort-level insights show that acute flare-ups are preceded by repeated refill lapses, the company and provider can deploy targeted clinical interventions instead of wasting budget on generic, superficial wellbeing perks.
Third, workplace productivity. Long before an employee triggers an expensive hospital claim, an unmanaged chronic condition leaks value through presenteeism, fatigue, and lost capacity. The UK Government's 2024 to 2025 survey revealed that 58% of British employees worked through illness over the previous twelve months despite feeling unfit for duty. Irregular medication regimens do not explain all presenteeism, but for chronic conditions, they play an undeniable role.
Crucially, this operational intelligence should correlate carefully with occupational health and absence patterns. It must never serve as a tool to police performance or push staff into disclosing medical decisions.
Implications for leadership
For HR leaders, missing adherence metrics make it impossible to evaluate whether condition-management investments actually work. A workplace diabetes initiative might boast impressive workshop attendance, yet provide zero visibility into whether attendees secure repeat medications regularly or attend follow-up reviews.
For Finance leaders, lack of treatment continuity data undermines accurate forecasting. Claims inflation becomes far clearer when you can separate demographic shifts and tariff adjustments from fragmented care routines and unmonitored chronic conditions.
For Risk managers, blind spots around adherence lead to misallocated capital. Without hard continuity data, businesses waste money on broad preventative campaigns while ignoring practical structural roadblocks, such as poor pharmacy access, fragmented communication, and neglected clinical follow-ups.
The solution is not intrusive employee tracking. The real goal is establishing renewal reviews that are clinically intelligent, properly aggregated, and focused on future health outcomes.
Five steps for the next renewal
Begin by demanding an adherence intelligence framework rather than transactional claim records. Instruct your broker or HMO to provide anonymised metrics such as refill intervals, medication possession ratios, treatment continuation rates, and follow-up reviews across key chronic cohorts, backed by explicit definitions of what the data shows.
Next, segment the data by risk and operational need. Evaluate trends across conditions, broad age groups, operational locations, and shift patterns wherever statistical sample sizes protect individual privacy. Small cohorts must be combined or masked to eliminate any possibility of re-identification.
Connect these medication metrics directly to practical business outcomes. Cross-reference adherence signals with unplanned acute care, repeated consultations, absence records, and occupational health referrals. The aim is uncovering practical correlations to guide clinical support, rather than assuming simplistic causation.
Build interventions around real, verified barriers. Depending on what the data uncovers, appropriate solutions might involve pharmacist-led consultations, simplified health communications, repeat-dispensing assistance, digital prompts, or faster clinical referrals. Follow NICE guidance closely: support programmes must solve identified individual hurdles rather than relying on blanket assumptions.
Finally, hold your HMO accountable to contractually agreed health milestones. Write measurable performance indicators directly into your renewal agreement, focusing on narrowed refill gaps in target cohorts, higher follow-up completion, reduced avoidable hospitalisations, and improved chronic management. Review these results quarterly rather than scrambling during annual contract renewals.
The next renewal conversation
Adherence metrics are not meant to displace claims data, but to give it strategic clarity. An HMO that only tallies historic healthcare consumption is showing you an expensive invoice; one that investigates care continuity, practical access, and clinical follow-through is helping you run a resilient business.
Forward-thinking organisations do not demand more intrusive employee data. They demand smarter questions, insist on privacy-preserving population intelligence, and tie healthcare spend to the only outcomes that truly matter: healthier staff, fewer avoidable hospital visits, dependable risk modelling, and an employee healthcare plan that protects people rather than just reimbursing bills. Stop treating your HMO renewal as an inevitable annual price hike, and demand that your provider prove whether your workforce is actually receiving the care you pay for.